These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28758820)

  • 1. Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii.
    Ghazi IM; Grupper M; Nicolau DP
    Infect Dis (Lond); 2017; 49(11-12):831-839. PubMed ID: 28758820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system.
    Ghazi IM; Grupper M; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2017 Jan; 16(1):2. PubMed ID: 28095918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29914950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia.
    Bernabeu-Wittel M; Pichardo C; García-Curiel A; Pachón-Ibáñez ME; Ibáñez-Martínez J; Jiménez-Mejías ME; Pachón J
    Clin Microbiol Infect; 2005 Apr; 11(4):319-25. PubMed ID: 15760430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of human intravenous immunoglobulin in combination with antimicrobials and human serum against multidrug-resistant isolates of Acinetobacter baumannii.
    de Lima FCG; de Araújo AR; do Nascimento AV; Bezerra Cavalcanti CL; Oliveira Júnior JB; Sandes JM; da Silva EM; de Freitas CF; Veras DL; Alves LC; Brayner FA
    Braz J Microbiol; 2023 Dec; 54(4):2845-2856. PubMed ID: 37904004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Zazo H; Martín-Suárez A; Lanao JM
    Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrastructural changes caused by the combination of intravenous immunoglobulin with meropenem, amikacin and colistin in multidrug-resistant Acinetobacter baumannii.
    Lima FCG; Oliveira-Júnior JB; Cavalcanti CLB; Veras DL; Freitas CF; Sandes JM; da Silva EM; da Rocha DAM; Alves LC; Brayner FA
    Microb Pathog; 2020 Dec; 149():104437. PubMed ID: 33045338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
    Cai X; Yang Z; Dai J; Chen K; Zhang L; Ni W; Wei C; Cui J
    Int J Antimicrob Agents; 2017 May; 49(5):609-616. PubMed ID: 28315729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin/sulbactam alone and in combination with amikacin.
    Savov E; Chankova D; Vatcheva R; Dinev N
    Int J Antimicrob Agents; 2002 Nov; 20(5):390-2. PubMed ID: 12431877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
    McCracken M; Mataseje LF; Loo V; Walkty A; Adam HJ; Hoban DJ; Zhanel GG; Mulvey MR;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model.
    Liu X; Zhao M; Chen Y; Bian X; Li Y; Shi J; Zhang J
    Int J Antimicrob Agents; 2016 Nov; 48(5):559-563. PubMed ID: 27670371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection.
    Principe L; Capone A; Mazzarelli A; D'Arezzo S; Bordi E; Di Caro A; Petrosillo N
    Microb Drug Resist; 2013 Oct; 19(5):407-14. PubMed ID: 23659601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii.
    Higgins PG; Stefanik D; Page MG; Hackel M; Seifert H
    J Antimicrob Chemother; 2012 May; 67(5):1167-9. PubMed ID: 22294643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
    Housman ST; Hagihara M; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia.
    Lee CH; Tang YF; Su LH; Chien CC; Liu JW
    Microb Drug Resist; 2008 Sep; 14(3):233-7. PubMed ID: 18707240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acinetobacter baumannii displays inverse relationship between meropenem resistance and biofilm production.
    Perez LR
    J Chemother; 2015 Feb; 27(1):13-6. PubMed ID: 24621167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain.
    Ko WC; Lee HC; Chiang SR; Yan JJ; Wu JJ; Lu CL; Chuang YC
    J Antimicrob Chemother; 2004 Feb; 53(2):393-5. PubMed ID: 14729739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
    Goyal K; Gautam V; Ray P
    Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.